Companion Diagnostic Tests in Oncology - Market Analysis and Forecasts

News provided by

M/S. Reportstack

20 May, 2014, 12:00 GMT

NEW YORK, LONDON, BERLIN and PARIS, May 20, 2014 /PRNewswire/ --

Market Domination by Non-Small Cell Lung Cancer Companion Diagnostic Tests 

Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts is a new oncology market research report announced by Reportstack. The major feature of the companion diagnostic testing market is the current domination of tests for mutations important in the prognosis and diagnosis of non-small cell lung cancer (NSCLC), with the two market leaders being Roche and Qiagen. According to GlobalData's forecast, in 2014, NSCLC companion diagnostic tests account for 55% of the market by value. While more human epidermal growth factor receptor 2 (HER2) tests are carried out, because the NSCLC tests have been principally more expensive molecular tests, rather than the cheaper immunohistochemistry (IHC) test that typifies HER2 testing, the value of the NSCLC market is considerably higher.

The companion diagnostic tests market is still evolving, but the market is led by Roche, Qiagen, Ventana, Dako, and Leica. Roche and Qiagen dominate the molecular testing market, while Ventana, Dako, and Leica also have a significant presence within the important IHC market. In most segments, there is little competition for tests, since only a few approved companion diagnostic tests are marketed. The exception is breast cancer HER2 testing, which, as the longest-established segment, has attracted the most competition. Laboratory decisions as to which brand of test to use are driven by clinical efficacy, which may vary considerably by regions.

"We have turned around our ERs [estrogen receptors] and HER2s in 1.9-2.9 days of taking a biopsy, so we now have the HER2 test available at the pre-operative discussion cancer [meeting], that has made the whole discussion so much more powerful. …We know they will have chemotherapy straight away - you can tell the patient that kind of thing, you know. If that became FISH, it couldn't be that quick always. So using an in-house test like IHC helps us do that." - says Key Opinion Leader

This report can help you in understanding:    

•   Overview of companion diagnostic tests in oncology, including core technologies, estimated procedure trends and disease overview
•   Current and future players companies involved in the space with portfolio assessment and SWOT analysis
•   Pipeline analysis: late-stage pipeline products with SWOT analysis and physician perception
•   Other key topics covered include identification of unmet needs, implications on the companion diagnostic market and how they may be overcome in the near future
•   Analysis of the market opportunities in addition to insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
•   Key countries covered: US, France, Germany, Italy, Spain, UK, Brazil, Japan, China, and India

Key Findings

  • The Companion Diagnostic test market for the 4 named cancers will grow at a CAGR of 4.9% over the forecast period. Developed regions, like US and EU showing lowest growth rates. While China and Brazil showing maximum growth rates.
  • Breast cancer HER2 testing dominates in terms of volume, but has been overtaken in terms of value by non-small cell lung cancer companion diagnostic testing, mostly for EGFR mutation status.
  • The market growth for companion diagnostic testing in the US and EU is heavily dependent on the acceptance into diagnostic guidelines and the stabilization of test reimbursement. Growth in developing economies is dependant upon patient access to laboratory testing and growth of professional pathology services

Amgen, Arno Therapeutics, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly and Co, Genentech, Pfizer, Syndax Pharmaceuticals, Amoy Diagnostics, Biogenex, BioMerieux, Dako,  Illumina, Leica Biosystems, Life Technologies, MolecularMD, Myriad Genetics, Qiagen, Roche Diagnostics, Siemens Healthcare and Ventana Medical Systems are some of the companies that are mentioned in this report. To order  this report kindly visit http://www.reportstack.com/product/154211/medipoint-companion-diagnostic-tests-in-oncology-global-analysis-and-market-forecasts.html

Other related  pharma industry reports :

Personalized Medicine in Oncology Partnering Terms and Agreements
Oncology Development Strategies
Neurovascular Interventions - Global Analysis and Market Forecasts
Breast Cancer Imaging - Global Analysis and Market Forecasts

About Reportstack™:

Reportstack is one of the leading distributors of market research reports in the world today. Reportstack provides access to over 50,000 company profiles and their strategic information like SWOT analysis, deals and partnerships analysis, merger & acquisition activity and new product launches. Reportstack is also a leader in the field of pharma and healthcare market research.

Contact Reportstack.com:
Nathan Gold
Senior Marketing Executive
Phone: +1 888-789-6604
Email: nathan@reportstack.com

Follow us: https://twitter.com/reportstack

Blogs: http://reportstack.blogspot.com